Portosystemic Shunt in Yorkshire Terriers: Management Guide

Comprehensive guide to congenital portosystemic shunts in Yorkshire Terriers — causes, clinical signs, tests (bile acids, imaging), medical therapy and surgical correction, with long-term care tips.

Quick Overview

• What it is: A congenital portosystemic shunt (PSS) is an abnormal vessel that allows blood from the gastrointestinal tract to bypass the liver and flow directly into the systemic circulation. This prevents normal detoxification and metabolism by the liver and commonly leads to hepatic encephalopathy and other systemic problems.
• Who's at risk: Small-breed dogs are overrepresented; Yorkshire Terriers are a commonly affected breed. Most congenital shunts present as extrahepatic shunts in toy/small breeds and are often diagnosed in puppies to young adults.
• Prognosis: With surgical correction (gradual attenuation) many dogs experience marked clinical improvement and long-term survival; reported improvement rates are high (often 70–90% in published series). Medical management can control signs but is generally palliative and carries a more guarded long-term outlook.

Pathophysiology (simple explanation)

The portal vein normally carries nutrient-rich, toxin-laden blood from the intestines to the liver for processing. A congenital portosystemic shunt is an abnormal vessel that diverts some or all of that blood away from the liver and into systemic veins (e.g., caudal vena cava). The liver receives less blood and less functional liver tissue develops. Toxins—most notably ammonia and other nitrogenous wastes and gut-derived substances—accumulate and can affect the brain (hepatic encephalopathy), kidneys, and other organs.

Types: extrahepatic (outside liver) are most common in small breeds, while intrahepatic shunts (within liver) are more common in large-breed dogs.

Breed-specific risk factors and prevalence

• Yorkshire Terriers are predisposed to congenital, extrahepatic portosystemic shunts. Other small-breed predisposed dogs include Maltese, Yorkshire, Miniature Schnauzers, Pugs, and Shih Tzus.
• Exact prevalence in the general dog population is low, but among young small-breed dogs with chronic hepatic signs the proportion is significant. Because PSS is congenital, affected dogs often show signs early in life (weeks to months) but milder cases may be diagnosed later.

Clinical signs and stages (hepatic encephalopathy)

Clinical signs range from subtle to severe depending on the amount of shunting and liver function. Signs are often intermittent and related to meals or stress.

Common signs

• Poor weight gain or stunted growth in puppies
• Reduced appetite, vomiting, diarrhea
• Increased drinking and urination
• Neurologic signs (hepatic encephalopathy): disorientation, ataxia, circling, head pressing, pacing, sudden blindness, tremors, seizures
• Strange behaviors: aggression, lethargy, decreased interaction
• Urinary signs: urate ammonium crystals/stones may form (ammonium biurate crystals)

• Grade I: mild changes in behavior, attention, learning
• Grade II: lethargy, disorientation, intermittent aggression
• Grade III: marked depression, ataxia, obtundation
• Grade IV: stupor or coma, severe seizures

Diagnostic approach

Aim: confirm functional liver impairment and locate/define the shunt anatomy.

1) Minimum database

• CBC: usually unremarkable but may show microcytosis
• Serum chemistry: low BUN, low cholesterol, low albumin (variable), hypoglycemia in severe cases
• Pre- and post-prandial bile acids: sensitive screening test. Elevated fasting or post-prandial bile acids strongly suggest hepatic dysfunction or shunting.
• Blood ammonia: can be elevated in hepatic encephalopathy but is labile and should be handled carefully (chilled tube, fasted sample). Elevated ammonia supports the diagnosis.
• Urinalysis: look for ammonium biurate crystals or urate stones (classical for PSS)

• Abdominal ultrasound with a skilled ultrasonographer: noninvasive, good at identifying many extrahepatic shunts, and can look for other liver abnormalities. Sensitivity depends on operator experience.
• CT angiography (CTA): increasingly considered the gold-standard anatomic test because it gives a detailed vascular map used for surgical planning. Requires general anesthesia.
• Nuclear scintigraphy (99mTc-pertechnetate or 99mTc-macroaggregated albumin): functional test that demonstrates extrahepatic shunting fraction and can confirm shunting but gives less anatomic detail.

• Referral to a board-certified veterinary surgeon or internist with experience in hepatic surgery and interventional radiology is strongly recommended, particularly if CTA is being considered or if surgical correction is being planned.

• Coagulation profile, crossmatching, and baseline hepatic parameters. Portal pressure measurement during surgery or interventional procedures helps guide the degree of attenuation.

Medical management (goals, drugs, diet)

Medical therapy aims to control hepatic encephalopathy and reduce toxin production until definitive treatment (surgery) is possible—or as long-term management if surgery is not an option.

Key components

1) Dietary management

• Feed a diet with restricted but high-quality protein (e.g., veterinary hepatic diets). Commercial hepatic diets from Hill's, Royal Canin, and Purina are commonly used and formulated to reduce nitrogenous waste while providing essential amino acids.
• Avoid sudden dietary changes, and use frequent small meals rather than one large meal.

• Lactulose (osmotic laxative that acidifies colon, traps ammonia as ammonium and increases stool frequency)

• Antibiotics to reduce ammonia-producing bacteria

3) Supportive medications

• Ursodeoxycholic acid (ursodiol) 10 mg/kg PO daily or divided q12–24h may be used to support bile flow and cholesterol metabolism when cholestasis is present.
• Antiemetics (maropitant, ondansetron) for vomiting, and IV fluids for dehydration and azotemia.
• Management of seizures: benzodiazepines acutely (careful with hepatic disease), phenobarbital is hepatically metabolized and should be used cautiously; levetiracetam is often a safer anticonvulsant if prolonged therapy needed (dosage commonly 20 mg/kg PO q8–12h in dogs; adjust per specialist advice).

• Clinical signs (especially neurologic changes), body weight, stool frequency/consistency, and periodic bile acids and chemistry panels.

Surgical correction and interventional options

Definitive care for congenital PSS is surgical or interventional closure/attenuation of the abnormal vessel. Goals are to redirect portal blood into the liver gradually to avoid acute portal hypertension.

Main techniques

1) Ameroid constrictor

• A metallic ring with hygroscopic inner core that slowly closes over 2–4 weeks; gradual occlusion reduces the risk of portal hypertension. Widely used for extrahepatic shunts in small dogs.

• Polyester or cellophane band placed around the shunt to cause gradual fibrosis and occlusion. Less expensive; variable rates of gradual attenuation.

• Acute complete ligation of the shunt may be possible if the dog tolerates it without portal hypertension; otherwise partial ligation is performed and combined with other gradual methods.

• Transvenous coil embolization or use of vascular plugs (percutaneous transvenous attenuation) is an option in selected cases and can be less invasive. Success depends on shunt anatomy and institutional expertise. Particularly useful for certain intrahepatic shunts and some extrahepatic shunts accessible via the vascular route.

• Reported clinical improvement rates after surgical attenuation are high; many series report 70–90% of dogs having significant or complete resolution of clinical signs. Long-term survival in many reports exceeds 80% when surgery is successful.
• Major risks include postoperative portal hypertension, persistent shunting, and anesthesia risks. Gradual attenuation methods (ameroid, cellophane) reduce the risk of portal hypertension compared with acute ligation.

Long-term management and monitoring

After definitive treatment (or when medical management is chosen), long-term follow-up includes:

• Regular rechecks with your veterinarian and specialist: physical exam and weight checks.
• Periodic bloodwork: chemistry panel, pre- and post-prandial bile acids (often at 1–3 months post-op, then every 6–12 months). Bile acids help detect residual shunting or declining liver function.
• Watch for late complications: persistent hepatic encephalopathy, formation of new shunts (rare), or portal hypertension sequelae.
• Continue hepatic diet and any medications as prescribed; tapering of lactulose/antibiotics may be possible if the dog is clinically normal and bile acids normalize — do this under veterinary guidance.

Prognosis and quality of life considerations

• With successful surgical attenuation, many Yorkshire Terriers return to a good quality of life and normal activity levels. Owners commonly report improvement in energy, appetite, behavior, and neurologic signs.
• Dogs managed medically can have useful quality of life for months to years, but the approach is palliative and clinical control may become more difficult over time.
• Early diagnosis and referral improve the likelihood of a good surgical outcome. Chronic changes in the liver (hypoplasia, fibrosis) may limit the degree of recovery.

Living With Portosystemic Shunt: Practical daily tips

• Diet: feed the prescribed hepatic diet in 2–4 small meals daily. Avoid table scraps and high-protein treats.
• Follow medication schedules strictly: lactulose and antibiotics should be given on time and as directed.
• Observe and record neurologic changes: note timing relative to meals, any stumbling, staring spells, head pressing, or seizure activity.
• Hydration and bowel movements: ensure easy access to water and monitor stool frequency — constipation can worsen encephalopathy.
• Preventive care: dental hygiene and vaccination per your vet; infections can precipitate encephalopathy.
• Travel and activities: most dogs do well with normal activity once stable; avoid prolonged fasting or stress immediately before planned events.

When to See Your Vet Urgently

Seek immediate veterinary care if your dog has:

• Repeated or prolonged seizures
• Sudden collapse, stupor, or coma
• Persistent vomiting or inability to keep down water
• Severe lethargy or not responding to stimuli
• Markedly decreased appetite for >24 hours

Practical notes on costs and referrals

• Diagnostic imaging (CTA), specialist consultation, and surgery costs vary by region and institution; discuss estimates and payment options with the referral center. Interventional radiology may be less invasive but still costly.
• Ask for referral to a board-certified veterinary surgeon (ACVS) or internal medicine specialist (ACVIM) experienced with PSS.

Bottom line

Congenital portosystemic shunts are an important cause of hepatic encephalopathy in Yorkshire Terriers. Early recognition (elevated bile acids, urinary ammonium biurate, neurologic signs), thorough imaging (ultrasound or CT angiography), and referral to a specialist for consideration of surgical attenuation provide the best chance for long-term recovery. Medical management is essential for stabilizing dogs and for those that cannot undergo surgery.

This guide is for educational purposes. Always consult your veterinarian for diagnosis and treatment.

Selected resources and further reading

• VCA Hospitals: Portosystemic shunts in dogs — client education and treatment overview
• ACVIM, journal articles and specialty texts on hepatic encephalopathy and portosystemic shunt surgery
• Veterinary teaching hospitals (e.g., UC Davis, Cornell) client education pages and surgical service descriptions

Frequently Asked Questions